Table 2.
Results of Fine–Gray model analysis for the cumulative incidence of relapse.
| Factor | Hazard ratio (95% CI) | P value |
|---|---|---|
| Age ≥ 65 years | 1.13 (0.68–1.87) | 0.64 |
| B symptoms | 1.12 (0.68–1.85) | 0.65 |
| Bone marrow invasion | 1.72 (1.03–2.88) | 0.04 |
| Extranodal lesions ≥ 2 | 1.07 (0.63–1.83) | 0.80 |
| Non GCB | 2.21 (1.42–3.43) | < 0.001 |
| PS ≥ 2 | 1.75 (0.78–3.92) | 0.18 |
| Post-treatment sIL-2R > UNL | 2.30 (1.46–3.61) | < 0.001 |
| Pre-treatment sIL2-R > UNL | 1.05 (0.59–1.88) | 0.86 |
| Stage III or IV | 2.82 (1.71–4.64) | < 0.001 |
CI confidence interval, GCB germinal centre B-cell-like type, high-int high-intermediate, IPI international prognostic index, PS performance status, sIL-2R soluble interleukin-2 receptor, UNL upper normal limit.